Regen Biopharma engages Biotech Research Group for NR2F6 IP assessment at $25k total

Regen BioPharma Inc

Engaged BRG to perform a GAP assessment of CRO work on NR2F6 checkpoint pre-clinical protocols, raw data, and completion report.
Total fee of $25,000 due immediately upon SOW signing; work to be completed by November 15, 2021.
Deliverables include a gap assessment report and a regulatory strategy work package for NR2F6 IP.
Scope of Work Order effective October 11, 2021, under existing Master Services Agreement dated May 12, 2021.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.